IBDEI1KL ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25457,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,25457,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,25457,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,25458,0)
 ;;=T43.205D^^92^1157^5
 ;;^UTILITY(U,$J,358.3,25458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25458,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,25458,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,25458,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,25459,0)
 ;;=T43.205S^^92^1157^6
 ;;^UTILITY(U,$J,358.3,25459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25459,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,25459,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,25459,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,25460,0)
 ;;=G25.71^^92^1157^7
 ;;^UTILITY(U,$J,358.3,25460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25460,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,25460,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,25460,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,25461,0)
 ;;=G24.02^^92^1157^8
 ;;^UTILITY(U,$J,358.3,25461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25461,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,25461,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,25461,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,25462,0)
 ;;=G21.0^^92^1157^12
 ;;^UTILITY(U,$J,358.3,25462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25462,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,25462,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,25462,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,25463,0)
 ;;=T50.905A^^92^1157^1
 ;;^UTILITY(U,$J,358.3,25463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25463,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Init Encntr
 ;;^UTILITY(U,$J,358.3,25463,1,4,0)
 ;;=4^T50.905A
 ;;^UTILITY(U,$J,358.3,25463,2)
 ;;=^5052160
 ;;^UTILITY(U,$J,358.3,25464,0)
 ;;=T50.905S^^92^1157^2
 ;;^UTILITY(U,$J,358.3,25464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25464,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Sequela
 ;;^UTILITY(U,$J,358.3,25464,1,4,0)
 ;;=4^T50.905S
 ;;^UTILITY(U,$J,358.3,25464,2)
 ;;=^5052162
 ;;^UTILITY(U,$J,358.3,25465,0)
 ;;=T50.905D^^92^1157^3
 ;;^UTILITY(U,$J,358.3,25465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25465,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,25465,1,4,0)
 ;;=4^T50.905D
 ;;^UTILITY(U,$J,358.3,25465,2)
 ;;=^5052161
 ;;^UTILITY(U,$J,358.3,25466,0)
 ;;=F45.22^^92^1158^1
 ;;^UTILITY(U,$J,358.3,25466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25466,1,3,0)
 ;;=3^Body Dysmorphic D/O
 ;;^UTILITY(U,$J,358.3,25466,1,4,0)
 ;;=4^F45.22
 ;;^UTILITY(U,$J,358.3,25466,2)
 ;;=^5003588
 ;;^UTILITY(U,$J,358.3,25467,0)
 ;;=F63.3^^92^1158^8
 ;;^UTILITY(U,$J,358.3,25467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25467,1,3,0)
 ;;=3^Trichotillomania (Hair-Pulling D/O)
 ;;^UTILITY(U,$J,358.3,25467,1,4,0)
 ;;=4^F63.3
 ;;^UTILITY(U,$J,358.3,25467,2)
 ;;=^5003643
 ;;^UTILITY(U,$J,358.3,25468,0)
 ;;=F06.8^^92^1158^4
 ;;^UTILITY(U,$J,358.3,25468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25468,1,3,0)
 ;;=3^OCD & Rel D/O d/t Phys Cond
 ;;^UTILITY(U,$J,358.3,25468,1,4,0)
 ;;=4^F06.8
 ;;^UTILITY(U,$J,358.3,25468,2)
 ;;=^5003062
 ;;^UTILITY(U,$J,358.3,25469,0)
 ;;=F42.4^^92^1158^2
 ;;^UTILITY(U,$J,358.3,25469,1,0)
 ;;=^358.31IA^4^2
